Xspray Pharma AB (publ) (STO:XSPRAY)
Sweden · Delayed Price · Currency is SEK 11.84
+0.04 (0.34%)
Nov 2, 2026, 3:59 PM CET
Xspray Pharma AB Earnings Call Transcripts
Fiscal Year 2026
-
The FDA's CRL for Dasynoc centers on facility status and a request for more commercial-scale batch data, with no new clinical or product quality concerns. Batch work is being accelerated for a 2026 resubmission, and commercialization plans remain on track pending regulatory clearance.